Anti-tumor activity of human T cells expressing the CC49-ζ chimeric immune receptor

Human Gene Therapy

Volumn 10, Issue 2, 1999, Pages 165-173

  McGuinness, Ryan P ^a   Ge, Ying ^a   Patel, Salil D ^a   Kashmiri, Syed V S ^b   Lee, Hyun Sil ^b   Hand, Patricia Horan ^b   Schlom, Jeffrey ^b   Finer, Mitchell H ^a   McArthur, James G ^a  

^a CELL GENESYS INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; MUCIN; SIGNAL PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CHIMERA; COLON CANCER; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNITY; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL DIVISION; FAS LIGAND PROTEIN; GLYCOPROTEINS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0033585433     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018968     Document Type: Article

References (21)

1. BLASSE, P. (1995). Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. APMIS Suppl. 103, 5-28.
2. FINER, M., DULL, T., QIN, L., FARSON, D., and ROBERTS, M. (1994). Kat: A high efficiency retroviral transduction system for primary human lymphocytes. Blood 83, 43-50.
3. GREINER, J., GUADAGNI, F., GOLDSTEIN, D., SMALLEY, R., BORDEN, E., SIMPSON, J., MOLINOLO, A., and SCHLOM, J. (1992). Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoma embryonic antigen on malignant ascites cells. J. Clin. Oncol. 10, 735-746.
4. HERBERMAN, R., HISERODT, J., and VUJANOVIC, J. (1987). Characteristics of effector cells and their progenitors in blood and spleen. Immunol. Today 8, 178-181.
5. HWU, P., YANG, J., COWHERD, R., TREISMAN, J., SHAFER, G., ESHHAR, Z., and ROSENBERG, S. (1995). In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55, 3369-3373.
6. Kashmiri, S., Shu, L., Padlan, E., Milenic, D., Schlom, J., and Horan-Hand, P. (1995). Generation, characterization and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14, 461-473.
7. MEREDITH, R., BUESCHEN, A., KHAZAEILI, M., PLOTT, W., GRIZLE, W., WHEELER, R., SCHLOM, J., RUSSEL, C., LIU, T., and LOBUGLIO, A. (1994). Treatment of metastic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35, 1017-1022.
8. MOLINOLO, A., SIMPSIN, J., THOR, A., and SCHLOM, J. (1990). Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res. 50, 1291-1298.
9. MORITZ, D., WELS, W., MATTERN, J., and GRONER, B. (1994). Cytotoxic T lymphocytes with a grafted recognition specificity for ERB-B2-expressmg tumor cells. Proc. Natl. Acad. Sci. U.S.A. 91, 4428-4322.
10. MURRAY, J., MACEY, D., KASI, L., RIEGER, P., CUNNINGHAM, J., BHADKAMKAR, V., ZHANG, H., SCHLOM, I., ROSENBLUM, M., and PODOLOFF, D. (1994). Phase II radioimmunotherapy trial with 131-I-CC49 in colorectal cancer. Cancer 73, 1057-1066.
11. National Cancer Institute (NCI). (1997). Cancer incidence in the United States. Cancer J. Clin. 47, 5-27.
12. PATEL, S., MOSKALENKO, M., SMITH, D., MASKE, B., FINER, M., and MCARTHUR, J. (1999). Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther. (in press).
13. RIDDELL, S., and GREENBERG, G. (1995). Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545-586.
14. RIDDELL, S., ELLIOTT, M., LEWINSOHN, D., GILBERT, M., WILSON, L., MANLEY, S., LUPTON, S., OVERELL, R., REYNOLDS, T., COREY, L., and GREENBURG, P. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223.
15. ROBERTS, M., QIN, L., ZHANG, D., SMITH, D., TRAN, A., DULL, T., GROOPMAN, J., CAPON, D., BYRN, R., and FINER, M. (1994). Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84, 2878-2889.
16. ROONEY, C., SMITH, C., NG, C., LOFTIN, S., LI, C., KRANCE, R., BRENNER, M., and HESLOP, H. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9-13.
17. SHIRAKI, K., TSUJI, N., ISELBACHER, K., and TAKAHASHI, H. (1997). Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. U.S.A. 94, 6420-6425.
18. SHU, L., QI, C., SCHLOM, J., and KASSHMIRI, S. (1993). Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 90, 7995-7999.
19. STANCOVISKI, I. SCHINDER, D., WAKS, T., YARDEN, Y., SELA, M., and ESHHAR, Z. (1993). Targeting of T lymphocytes to Neu/Her-2-expressing cells using chimeric receptor single chain Fv receptors. J. Immunol. 151, 6577-6582.
20. WALKER, P., SAAS, P., and DIETRICH, P. (1997). Role of Fas ligand (CD95L) in immune escape - the tumor strikes back. J. Immunol. 158, 4521-4524.
21. YANNELLI, J., HYATT, C., MCCONNELL, S., HINES, K., JACKNIN, L., PARKER, L., SANDERS, M., and ROSENBERG, S. (1996). Growth of tumor infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int. J. Cancer 65, 413-421.